Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Ovarian Hyperstimulation Syndrome

• To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects
• Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
• Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
• Ovarian Hyperstimulation Syndrome Using Calcium Infusion
• Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
• Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
• Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
• Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
• Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality
• The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation
• Montelukast for Prevention & Treatment of OHSS
• Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
• Resveratrol as a Preventive Treatment of OHSS
• Preventive Application of GnRH Antagonist on Early OHSS
• Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
• Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome
• Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
• Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome
• Follicular Steroid Genesis in Controlled Ovarian Stimulation
• Efficacy and Safety of Medication Used to Stimulate Ovulation
• The Letrozole Administration During Luteal Phase
• Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS
• The Influence of Timing of Cabergoline Initiation on Prevention of OHSS
• Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome
• Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)
• Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation
• Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome
• Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
• Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS
• Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve
• Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
• Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
• Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
• Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
• FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
• Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
• Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
• Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
• GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulation
• Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
• Ovarian Hyperstimulation Syndrome and Cabergoline
• Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
• Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention
• Endometrial Receptivity After GnRH Agonist Triggering
• Calcium for Prevention of Ovarian Hyperstimulation Syndrome
• Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
• GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome
• Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
• Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
• Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program
• The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
• Short Versus Long Protocol for IVF and IVF+ICSI
• Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
• Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
• Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
• The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome
• Cabergoline Reduces OHSS
• Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
• The Use of GnRH Agonist Trigger in the Prevention of OHSS
• Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide